Ignite Creation Date:
2024-05-05 @ 10:58 PM
Last Modification Date:
2024-10-26 @ 10:26 AM
Study NCT ID:
NCT01223586
Status:
COMPLETED
Last Update Posted:
2012-04-24
First Post:
2010-10-18
Brief Title:
Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome
Sponsor:
Kyoto University
Organization:
Kyoto University Hospital
Study Overview
Official Title:
Extended Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Ex JAPAN-ACS
Brief Summary:
The objective of this study is to verify the relationship between coronary plaque regression and cardiovascular prevention in long term follow up of the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome JAPAN-ACS study NCT00242944 In addition the effect of serum lipid levels or different type of statins on cardiovascular prevention will also be examined
Detailed Description:
Several previous multicenter studies using intravascular ultrasound IVUS imaging have revealed that statins attenuate the progression of atherosclerosis or even provide regression of plaque volume Indeed the Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome JAPAN-ACS trial NCT00242944 has revealed that early aggressive statin therapy in patients with acute coronary syndrome ACS significantly reduces the plaque volume of non-culprit coronary lesions On the other hands a direct relationship between atheroma progression and regression on IVUS and clinical events has not been clearly defined To verify that relationship long term follow up of the JAPAN-ACS study will be performed Clinical outcome of patients with regressed plaque and progressed plaque will be compared In addition the objectives of this study are to evaluate the effect of serum lipid levels or different type of statins on cardiovascular prevention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None